| 证券简称：塞力医疗 | 公告编号：2025-079 | | --- | --- | | 债券简称：塞力转债 | | | 证券代码：603716 债券代码：113601 | | 选举鲁翌先生担任公司第五届董事会职工董事，任期自公司 2025 年第一次 职工代表大会选举通过之日起至第五届董事会任期届满之日止。鲁翌先生将与公 司2024年第三次临时股东大会选举产生的8名董事共同组成公司第五届董事会。 届时，公司第五届董事会成员将由原来的 8 人调整为 9 人。 塞力斯医疗科技集团股份有限公司 本次职工董事选举产生后，公司第五届董事会中兼任公司高级管理人员职 务的董事以及由职工代表担任的董事人数，总计未超过公司董事总数的二分之一， 符合有关法律法规、规范性文件及《公司章程》的规定。 关于选举职工董事的公告 鲁翌先生简历详见附件。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 根据《公司法》等法律法规、规范性文件及《公司章程》的有关规定，塞力 斯医疗科技集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 ...

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 15 日 (二)股东大会召开的地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 A 会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 789 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 43,839,503 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 21.2618 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 证券代码：603716 证券简称：塞力医疗 公告编号：2025-078 塞力斯医疗科技集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。本次会议的召集、召开、表决方 ...

国浩律师（上海）事务所 国浩律师（上海）事务所 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 9 月 国浩律师（上海）事务所 法律意见书 关 于 塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会 关于塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会之法律意见书 致：塞力斯医疗科技集团股份有限公司 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年第四次临 时股东大会于 2025 年 9 月 15 日召开。国浩律师（上海）事务所（以下简称 "本所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第四次临时 股东大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》《 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 31.06 | 1.37% | 8.70万 | | 2.70亿 | | 603122 | 合富中国 | 6.80 | 1.04% | 5.62万 | | 3796.18万 | | 002589 | 瑞康医药 | 2.98 | 1.02% | 35.12万 | | 1.04亿 | | 600833 | 第一医药 | 13.85 | 0.80% | 12.19万 | | 1.70亿 | | 601607 | 上海医药 | 18.13 | 0.67% | 16.81万 | | 3.05亿 | | 603939 | 益丰药房 | 25.86 | 0.39% | 6.62万 | | 1.71亿 | | 000078 | 海王生物 | 2.67 | 0.38% | 36.07万 | | 9585.89万 | | 000411 | 英特集团 | 11.47 | 0.17% | 4.70万 | | 5370.37万 ...

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Saily Medical Technology Group Co., Ltd., indicating a significant portion of shares has been pledged, but the company maintains that this will not affect its operations or control [2][5][6]. Group 1: Share Pledge Details - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, representing 10.30% of the total share capital, and has pledged 3,000,000 shares recently [2]. - After the recent pledge, Saihai Technology has a total of 17,000,000 pledged shares, which is 78.55% of its holdings and 8.09% of the total share capital [2]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares (4.58% of total share capital) and has pledged 5,300,000 shares, which is 55.01% of his holdings [2]. Group 2: Future Pledge and Financing - Within the next six months, 6,000,000 shares are set to mature, accounting for 19.18% of their holdings and 2.86% of total share capital, with a corresponding financing balance of 14.61 million yuan [5]. - In the next year, an additional 9,000,000 shares will mature, representing 28.78% of their holdings and 4.28% of total share capital, with a financing balance of 36 million yuan [5]. - The funds from the recent pledge are primarily intended to repay previous pledge financing debts, and the company asserts that it has the ability to repay these debts [5][6]. Group 3: Risk Management and Impact - The company states that the pledge will not impact its operations, main business, financing costs, or ongoing viability, and there is no risk of a change in actual control [6]. - The credit status of Saihai Technology and Mr. Wen Wei is reported to be good, with manageable pledge risks, and they are prepared to take measures if stock prices approach warning or liquidation levels [6].

Group 1 - The company, Saily Medical, announced that its controlling shareholder, Saihai Technology, has pledged 3 million shares, bringing the total pledged shares to 17 million, which is 78.55% of Saihai's holdings and 8.09% of the total shares outstanding [1] - The actual controller, Mr. Wen Wei, holds approximately 9.63 million shares, representing 4.58% of the total shares, and has pledged 530,000 shares, which is 55.01% of his holdings and 2.52% of the total shares [1] - As of the announcement date, the total pledged shares by Saihai Technology and Mr. Wen Wei amount to 22.3 million, accounting for 71.3% of their combined holdings and 10.61% of the total shares outstanding [1] Group 2 - For the fiscal year 2024, Saily Medical's revenue composition is projected to be 97.09% from commercial activities and 2.91% from industrial activities [1] - The company's market capitalization is currently valued at 6.6 billion yuan [2]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 10.30%（截至 2025 年 8 月 20 日总股 本，下同）。近日，赛海科技将其中 3,000,000 股股份办理了质押登记手续。本 次质押手续办理完毕后，赛海科技累计质押公司股份 17,000,000 股，占其持有 公司股份比例为 78.55%，占公司总股本比例为 8.09%。 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 4.58%。温伟先生累计质押公司股份 5,300,000 股，占其持 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The innovative drug concept stocks are showing strength, with Seer Medical hitting the daily limit up [1] - Guangsheng Tang increased by over 7%, indicating positive market sentiment [1] - Other companies such as Yuandong Biological, Huahai Pharmaceutical, Zhaoyan New Drug, and Enhua Pharmaceutical also experienced upward movement [1]

Group 1 - The core viewpoint of the news is that Sely Medical's stock has increased by 5.02%, reaching a price of 29.89 yuan per share, with a trading volume of 3.09 billion yuan and a turnover rate of 5.02%, resulting in a total market capitalization of 62.81 billion yuan [1] - Sely Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Sely Medical's main business is as follows: IVD business accounts for 39.91%, SPD business accounts for 38.01%, and pure sales account for 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under Caitong Fund ranks among the top shareholders. Caitong Advantage Industry Rotation Mixed A (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 920,100 yuan [2] - Caitong Advantage Industry Rotation Mixed A (011201) was established on February 9, 2021, with a latest scale of 536 million yuan. Year-to-date return is 27.92%, ranking 2916 out of 8174 in its category; the one-year return is 47.03%, ranking 3325 out of 7981; and since inception, it has a loss of 22.16% [2]